Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2
MS Bekheit, SS Panda, AS Girgis - European Journal of Medicinal …, 2023 - Elsevier
The SARS-CoV-2 pandemic is considered as one of the most disastrous pandemics for
human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of …
human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of …
[HTML][HTML] An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: promises and challenges
X Xu, Y Chen, X Lu, W Zhang, W Fang, L Yuan… - Biochemical …, 2022 - Elsevier
The highly transmissible variants of SARS-CoV-2, the causative pathogen of the COVID-19
pandemic, bring new waves of infection worldwide. Identification of effective therapeutic …
pandemic, bring new waves of infection worldwide. Identification of effective therapeutic …
A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase
A Shannon, V Fattorini, B Sama, B Selisko… - Nature …, 2022 - nature.com
The guanosine analog AT-527 represents a promising candidate against Severe Acute
Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …
Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …
Rutin is a low micromolar inhibitor of SARS-CoV-2 main protease 3CLpro: Implications for drug design of quercetin analogs
The pandemic, due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has
stimulated the search for antivirals to tackle COVID-19 infection. Molecules with known …
stimulated the search for antivirals to tackle COVID-19 infection. Molecules with known …
Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews
Convalescent plasma (CP) from patients recovered from COVID-19 is one of the most
studied anti-viral therapies against SARS-COV-2 infection. The aim of this study is to …
studied anti-viral therapies against SARS-COV-2 infection. The aim of this study is to …
Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database
Abstract On October 2020, the US Food and Drug Administration (FDA) approved remdesivir
as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing …
as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing …
In vitro and in vivo suppression of SARS‐CoV‐2 replication by a modified, short, cell‐penetrating peptide targeting the C‐terminal domain of the viral spike protein
Peptides are promising therapeutic agents for COVID‐19 because of their specificity, easy
synthesis, and ability to be fine‐tuned. We previously demonstrated that a cell‐permeable …
synthesis, and ability to be fine‐tuned. We previously demonstrated that a cell‐permeable …
Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial
N Akbari, A Ostadrahimi, H Tutunchi… - Journal of Trace …, 2022 - Elsevier
Background The present study aimed to assess the therapeutic effects of boron citrate and
oleoylethanolamide supplementation in patients with COVID-19. Methods Forty adult …
oleoylethanolamide supplementation in patients with COVID-19. Methods Forty adult …
Contemporary narrative review of treatment options for COVID‐19
L Shang, DC Lye, B Cao - Respirology, 2021 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) pandemic is ongoing and many drugs
have been studied in clinical trials. From a pathophysiological perspective, anti‐viral drugs …
have been studied in clinical trials. From a pathophysiological perspective, anti‐viral drugs …
[PDF][PDF] A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines
The aim of this study is to comprehensively analyze previous viral vaccine programs and
identify potential challenges and effective measures for the COVID-19 vaccine program …
identify potential challenges and effective measures for the COVID-19 vaccine program …